Products - Molecular genetic - Molecular - SARS-CoV-2 / COVID-19

SARS-CoV-2 / COVID-19

Contact our Molecular Genetic Product Team for further details and information

Information

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV) belongs to the family of coronaviruses and, like SARS-CoV, is classified in the genus Betacoronavirus. At the end of 2019, it caused an infection wave that rapidly spread worldwide and was declared a pandemic by the WHO in March 2020. Just a few days after the first report about patients with pneumonia of unclear origin, SARS-CoV-2 was identified as the causative pathogen and the associated disease named COVID-19. SARS-CoV-2 is mainly transmitted via aerosols during speaking, breathing, coughing or sneezing or at close contact with an infected person.

Diagnostic Guidelines

The incubation period is usually three to seven, maximally 14 days. The symptoms and severity of SARS-CoV-2 infection can vary significantly. The most common symptoms encompass fever, coughing, breathing difficulties and fatigue. Therefore, in the majority of patients, the infection resembles a cold with light fever, with irregular lung infiltrates. Some patients, especially older and chronically ill persons, develop severe acute respiratory distress syndrome.

Suitable methods for the diagnosis of SARS-CoV-2 infections are the detection of viral RNA by reverse transcriptase polymerase chain reaction (RT-PCR) or of virus protein by means primarily in sample material from the upper (nasopharyngeal or oropharyngeal swab) or lower respiratory tract (bronchoalveolar lavage fluid, tracheal secretion, sputum, etc.). PCR allows detection of the pathogen even in subclinical or asymptomatic courses in a few days after virus contact and up to 14 days after onset of possible symptoms. Moreover, the combination of different parameters in an RT-PCR allows detecting and differentiating SARS-CoV-2 and other respiratory pathogens such as influenza viruses in one test.

The determination of antibodies enables confirmation of SARS-CoV-2 infection in patients with typical symptoms and in suspected cases. It also contributes to monitoring and outbreak control. For significant serological results, two patient samples should be investigated, one from the acute phase (week 1 of the illness) and one from the convalescent phase (3 to 4 weeks later).

SARS-CoV-2 / COVID-19 products

For Research Use Only. Not For Use In Diagnostic Procedures.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.

wdt_ID Method Parameter Substrate Species/ Antigen
768 ELISA SARS-CoV-2 antigen-coated
microplate wells
recombinant S1 antigen
of SARS-CoV-2
769 PCR EURORealTime SARS-CoV-2
770 ELISA SARS-CoV-2 NCP
Method Parameter Substrate Species/ Antigen
Contact our Molecular Genetic Product Team for further details and information
Download Our Latest <br/>EUROIMMUN US Product Catalog

Product Catalog

Download Our Latest
EUROIMMUN US Product Catalog

Download The EUROIMMUN US Product Catalog (PDF)

2024 EUROIMMUN US

Privacy Policy | Sitemap